| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. | |
|
Featured Story | | | Monday, June 5, 2017 The annual ASCO meeting often throws new light on old drugs—and old dealmaking. This year, it’s last summer’s most ballyhooed M&A deal—Pfizer’s $14 billion buyout of Medivation—that doesn’t look so impressive anymore, thanks to data rolled out over the weekend. |
|
|
| This week's sponsor is Alcami. | |  | [Webinar] Get on Track with Serialization: Lessons Learned
Tuesday, June 13 | 2pm ET / 11am PT
As the pharmaceutical industry races to meet the DSCSA deadline, challenges and complexities of serialization are becoming clear. Join Alcami to discuss lessons learned, mistakes to avoid and gain insight on how to achieve compliance. Register Now! |
Top Stories Of The Week Sunday, June 4, 2017 Chinese firm Nanjing Legend Biotech grabbed much attention at ASCO, showing that its CAR-T candidate could be a safe and effective way to treat relapsed or refractory multiple myeloma. Wednesday, June 7, 2017 It’s been a big week for CAR-T at ASCO, and now Novartis has revealed the long-awaited Juliet data for its CAR-T candidate at a Swiss conference. Tuesday, June 6, 2017 Jeffrey Konrad started taking AbbVie’s heavily advertised testosterone drug AndroGel in 2010 and suffered a heart attack shortly thereafter. Now he’s one of 4,100 men pressing claims that AndroGel caused their cardiovascular problems, and the first to offer testimony in a class action unfolding in an Illinois federal court. Tuesday, June 6, 2017 Formulary exclusions, pricing, biosimilars and cardiovascular outcomes data have impacted the U.S. diabetes space. We’ve compiled last year’s U.S. sales rankings for you, along with some insight into what to expect for each of the top meds going forward. Monday, June 5, 2017 Considering that the treatment options for patients with advanced ovarian cancer are severely limited, it’s no surprise that British researchers kicked up some buzz at the American Society of Clinical Oncology annual meeting on June 3, when they announced positive results from a phase 1 trial of a brand-new compound. Wednesday, June 7, 2017 Medtronic’s hybrid closed-loop system, the world’s first “artificial pancreas,” is hitting the U.S. market. The system is the only FDA-approved insulin pump that automatically delivers basal insulin to control blood glucose levels in people with Type 1 diabetes. Tuesday, June 6, 2017 It’s no secret that combination studies featuring checkpoint inhibitors and cancer vaccines have been popping up left and right. Now, an EP Vantage snapshot shows just how many trials are underway—and which drugmakers are leading the pack. Tuesday, June 6, 2017 Albany, New York-based AMRI has agreed to a buyout worth more than $920 million as the M&A market for contract manufacturers continues to run hot. The deal comes just weeks after one of the big boys among CDMO players, Patheon, agreed to an acquisition valued at $7.2 billion. Wednesday, June 7, 2017 To raise capital for expansion, WuXi Biologics is pricing its shares at HK$20.60, the top end of its marketing range, thus valuing the IPO at HK$3.98 billion ($510 million), Bloomberg reports, quoting people familiar with the deal. |
|
